Mesoblast (ASX:MSB) will issue 10.2 million ordinary shares to Osiris Therapeutics as contingent consideration in relation to the approval of its cell treatment by the US Food and Drug Administration (FDA), according to a Monday Australian bourse filing.
The FDA approved the firm's mesenchymal stromal cell therapy, Ryoncil, in December 2024, according to an earlier filing.
The shares will be subject to voluntary escrow for 12 months from the date of issue, the filing said.
Mesoblast's shares fell 6% during trading on Tuesday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。